Literature DB >> 15014890

[Dysfunction of a kidney allograft with life-threatening results].

S Harendza1, M Ahrens, A Schneider, B Pfalzer, A Erbersdobler, U Helmchen, A C Feller, R A K Stahl.   

Abstract

Post-transplant lymphoproliferative disease (PTLD) is a serious complication after organ transplantation. We describe the case of a 45-year old patient who developed an EBV associated B-cell lymphoma in a cadaveric renal allograft. This case underscores the importance of considering PTLD as possible differential diagnosis for allograft dysfunction. Careful diagnostic evaluation should be undertaken in patients who present with risk factors for development of PTLD such as high doses of immunosuppression for rejection therapy, suspicious EBV serologies or negative EBV serologies before transplantation. PTLD can be of donor or recipient origin. Independent of its origin PTLD needs an immediate therapy which depends on the histology of the lymphoma and on the clinical conditions of the patient. Therapeutic options are reduction of the immunosuppression, chemotherapy or radiation, administration of lymphocyte-specific antibodies or removal of the kidney allograft.

Entities:  

Mesh:

Year:  2004        PMID: 15014890     DOI: 10.1007/s00108-004-1171-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

Review 1.  Detection of Epstein-Barr virus in posttransplantation T cell lymphoma in a kidney transplant recipient: case report and review.

Authors:  C Frías; R Lauzurica; M Vaquero; J M Ribera
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

Review 2.  Primary renal lymphoma does exist: case report and review of the literature.

Authors:  G Stallone; B Infante; C Manno; N Campobasso; G Pannarale; F P Schena
Journal:  J Nephrol       Date:  2000 Sep-Oct       Impact factor: 3.902

3.  Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.

Authors:  I A Darenkov; M A Marcarelli; G P Basadonna; A L Friedman; K M Lorber; J G Howe; J Crouch; M J Bia; A S Kliger; M I Lorber
Journal:  Transplantation       Date:  1997-09-27       Impact factor: 4.939

4.  Diagnosis and characterization of non-Hodgkin's lymphoma in a patient with acute renal failure.

Authors:  J S Miyake; S Fitterer; D C Houghton
Journal:  Am J Kidney Dis       Date:  1990-09       Impact factor: 8.860

5.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.

Authors:  F Wang; C D Gregory; M Rowe; A B Rickinson; D Wang; M Birkenbach; H Kikutani; T Kishimoto; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder.

Authors:  C G Schaar; J W van der Pijl; B van Hoek; J W de Fijter; R A Veenendaal; P M Kluin; J H van Krieken; A Hekman; W E Terpstra; R Willemze; H C Kluin-Nelemans
Journal:  Transplantation       Date:  2001-01-15       Impact factor: 4.939

7.  Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.

Authors:  Valter Duro Garcia; José Luz Bonamigo Filho; Jorge Neumann; Laura Fogliatto; Anna Maria Geiger; Clotilde Druck Garcia; Vivianne Barros; Elizete Keitel; Antonio Eduardo Bittar; Auri Ferrera des Santos; Sergio Roithmann
Journal:  Transpl Int       Date:  2003-02-13       Impact factor: 3.782

Review 8.  Lymphomas in the immunocompromised patient.

Authors:  M D DeMario; D N Liebowitz
Journal:  Semin Oncol       Date:  1998-08       Impact factor: 4.929

9.  Epstein-Barr virus lymphoproliferative disease of donor origin after kidney transplantation: a case report.

Authors:  E Renoult; B Aymard; M J Grégoire; A Bellou; J Hubert; D Hestin; J Audouin; P Lederlin; M Kessler
Journal:  Am J Kidney Dis       Date:  1995-07       Impact factor: 8.860

10.  Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.

Authors:  G Opelz; R Henderson
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.